People: LipoScience Inc (LPDX.OQ)
LPDX.OQ on NASDAQ Stock Exchange Global Market
5.55USD
12:52pm EDT
5.55USD
12:52pm EDT
Price Change (% chg)
$-0.88 (-13.69%)
$-0.88 (-13.69%)
Prev Close
$6.43
$6.43
Open
$6.30
$6.30
Day's High
$6.30
$6.30
Day's Low
$5.42
$5.42
Volume
19,651
19,651
Avg. Vol
22,572
22,572
52-wk High
$11.67
$11.67
52-wk Low
$5.42
$5.42
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Buzz Benson |
58 | 2011 | Independent Chairman of the Board |
Richard Brajer |
52 | 2003 | President, Chief Executive Officer, Director |
Lucy Martindale |
50 | 2001 | Chief Financial Officer, Executive Vice President |
James Otvos |
57 | 2011 | Chief Financial Officer, Executive Vice President |
Timothy Fischer |
51 | 2012 | Chief Operating Officer |
Ashok Marin |
45 | 2012 | Chief Compliance Officer, Vice President, General Counsel, Secretary |
E. Duffy McDonald |
60 | 2012 | Vice President - Human Resources and Organizational Effectiveness |
Thomas Clement |
58 | 2012 | Vice President - Regulatory and Quality Affairs |
Robert Honigberg |
53 | 2011 | Vice President - Medical Affairs, Chief Medical Officer |
Robert Greczyn |
61 | 2011 | Independent Director |
John Landon |
72 | 2007 | Independent Director |
Daniel Levangie |
62 | 2010 | Independent Director |
Woodrow Myers |
59 | 2011 | Independent Director |
Roderick Young |
69 | 2008 | Independent Director |
Biographies
| Name | Description |
|---|---|
Buzz Benson |
Mr. Buzz Benson is an Independent Chairman of the Board of LipoScience Inc., Mr. Benson has served as a director of the Company since 2001 and as Chairman of the Board since June 2011. Mr. Benson is a managing director and president of SightLine Partners LLC. SightLine manages a series of private equity funds that provide creative financial solutions to later stage medical technology companies and financial alternatives to the existing investors in these companies. SightLine Partners was formed in 2004 to acquire the healthcare venture capital funds of Piper Jaffray Companies. Prior to co-founding SightLine Partners, he was a Managing Director and President of Piper Jaffray Companies from 1992 to 2004. From 1986 to 1992, he was co-head of the Piper Jaffray healthcare investment banking group. Prior to joining Piper Jaffray Companies in 1986, Mr. Benson was a partner at Stonebridge Capital, a partnership investing in emerging publicly traded companies. Previously, he was an investment officer with Cherry Tree Ventures and a manager in the public accounting firm of Arthur Andersen & Co. Mr. Benson holds a B.S. degree in accounting from St. John’s University and was a Certified Public Accountant. |
Richard Brajer |
Mr. Richard O. Brajer is President, Chief Executive Officer, Director of LipoScience Inc., since 2003. From 1990 to 2003, Mr. Brajer was with Becton Dickinson and Company, or BD, a medical technology company, where he served in a number of senior management positions, both in the United States and in Europe, ultimately serving as president of BD’s worldwide diagnostic business. He served as a corporate officer of BD. From 1987 to 1990, Mr. Brajer served as a consultant with McKinsey & Company. He began his career as a product development engineer with the Procter & Gamble Company. Mr. Brajer received a B.S. degree in chemical engineering from Purdue University and an M.B.A. degree from Stanford University. |
Lucy Martindale |
Ms. Lucy G. Martindale is an Chief Financial Officer, Executive Vice President of LipoScience Inc., since 2001. From 1996 to 2001, she served as vice president and finance director of GlaxoWellcome Research & Development, a pharmaceutical research and development company. Ms. Martindale held positions with GlaxoWellcome, Inc., a pharmaceutical company, from 1984 to 1996, including vice president, corporate planning and analysis. Prior to joining Glaxo, Ms. Martindale worked at Bristol-Myers Squibb, a pharmaceutical company, and American Hospital Supply Corporation, a supplier of hospital equipment and products. Ms. Martindale received a B.S. degree in business from Indiana University and an M.B.A. degree from Campbell University. |
James Otvos |
Dr. James D. Otvos is Chief Financial Officer, Executive Vice President of LipoScience Inc. Dr. Otvos is a founder of the company and has served as Chief Scientific Officer since its inception. He has served as Executive Vice President since 1999 and as a member of the Board of Directors until March 2011. From 1990 to 2000, Dr. Otvos was a professor of biochemistry at North Carolina State University, where he is an adjunct professor. Dr. Otvos received a Ph.D. degree in comparative biochemistry from the University of California-Berkeley and performed his postdoctoral training in molecular biophysics at Yale University. |
Timothy Fischer |
Mr. Timothy J. Fischer is Chief Operating Officer of LipoScience Inc., since January 2012. Previously served as Vice President of Research and Development from September 2010 to January 2012. From December 2006 to September 2010, Mr. Fischer was with BD, where he served as vice president of development for BD’s women’s health and cancer business. From 2003 to December 2006, he served as vice president of product development for TriPath Oncology, a diagnostic company in the field of women’s health. Mr. Fischer received a B.S. degree in biology from Indiana University. |
Ashok Marin |
Mr. Ashok D. Marin is Chief Compliance Officer, Vice President, General Counsel, Secretary of LipoScience Inc., since June 2012. From February 2010 to June 2012, Mr. Marin was senior counsel, global compliance for the medical diagnostics business of GE Healthcare, a diversified healthcare business. From 2001 to February 2010, Mr. Marin served in the legal department of Sanofi U.S., a pharmaceutical company, in roles of increasing responsibility, most recently as assistant general counsel. He received B.A and J.D. degrees from Fordham University. |
E. Duffy McDonald |
Mr. E. Duffy McDonald is Vice President - Human Resources and Organizational Effectiveness of LipoScience Inc., since October 2011. From May 2009 to September 2011, Dr. Honigberg served as chief medical officer for research & measurement for URAC, formerly known as the Utilization Review Accreditation Commission, an accreditation commission in Washington, D.C., and as a consultant to a number of start-up companies in diagnostics, devices and healthcare delivery. From April 2006 to April 2009, Dr. Honigberg was the chief medical officer, global medical affairs and clinical strategy, for GE Healthcare, and from 1999 to 2006, he was the chief medical officer and vice president of medical and clinical affairs at Ethicon Endo-Surgery, a Johnson & Johnson operating company. Prior to 1999, Dr. Honigberg also directed clinical trials, medical affairs operations and strategy for Ortho Biotech and Schering-Plough. Dr. Honigberg received a B.A. degree in economics from Duke University, an M.D. degree from the Feinberg School of Medicine of Northwestern University and an M.B.A. degree from Northwestern University. |
Thomas Clement |
Mr. Thomas S. Clement is Vice President - Regulatory and Quality Affairs of LipoScience Inc. From January 2009 to January 2011, he served as vice president of global regulatory and clinical affairs for QIAGEN N.V., a provider of sample and assay technology. From 2002 to 2008, Mr. Clement was vice president of quality and regulatory affairs for Roche Molecular Systems. From 1989 to 2002, he was director of regulatory affairs for Organon Teknika Corporation. From 1988 to 1989, he served as manager of regulatory affairs for Amersham, and from 1984 to 1988, he was manager of quality for Biotech Research Laboratories. Mr. Clement received a B.S. degree in business administration from the University of Maryland. |
Robert Honigberg |
Dr. Robert M. Honigberg is Vice President - Medical Affairs, Chief Medical Officer of LipoScience Inc., since October 2011. From May 2009 to September 2011, Dr. Honigberg served as chief medical officer for research & measurement for URAC, formerly known as the Utilization Review Accreditation Commission, an accreditation commission in Washington, D.C., and as a consultant to a number of start-up companies in diagnostics, devices and healthcare delivery. From April 2006 to April 2009, Dr. Honigberg was the chief medical officer, global medical affairs and clinical strategy, for GE Healthcare, and from 1999 to 2006, he was the chief medical officer and vice president of medical and clinical affairs at Ethicon Endo-Surgery, a Johnson & Johnson operating company. Prior to 1999, Dr. Honigberg also directed clinical trials, medical affairs operations and strategy for Ortho Biotech and Schering-Plough. Dr. Honigberg received a B.A. degree in economics from Duke University, an M.D. degree from the Feinberg School of Medicine of Northwestern University and an M.B.A. degree from Northwestern University. |
Robert Greczyn |
Mr. Robert J. Greczyn is an Independent Director of LipoScience Inc., since March 2011. From 2000 to 2010, he was the chief executive officer of Blue Cross Blue Shield of North Carolina, where he served on the board of the Blue Cross Blue Shield Association and chaired several committees until his retirement in 2010. From 2006 to 2008, Mr. Greczyn was chairman of the board of the Council for Affordable Quality Care, an alliance of chief executive officers of the nation’s health insurers working to simplify healthcare transactions. In addition, Mr. Greczyn, served as a director of MModal Inc., a publicly held provider of interactive clinical documentation and speech understanding technology, from October 2011 until its acquisition in August 2012. Mr. Greczyn received an M.P.H. degree in health policy from the University of North Carolina at Chapel Hill and a B.A. degree in psychology from East Carolina University. |
John Landon |
Mr. John H. Landon is an Independent Director of LipoScience Inc., since 2007. Mr. Landon served as the vice president and general manager of Medical Products for E.I. DuPont de Nemours and Company, or DuPont, from 1992 until his retirement in 1996. Prior to that, Mr. Landon served in capacities at DuPont, including vice president and general manager, diagnostics and biotechnology from 1990 to 1992, director of diagnostics from 1988 to 1990, business director of diagnostic imaging from 1985 to 1988 and in various other professional and management positions from 1962 to 1985. Mr. Landon served as chairman of the board of Cholestech Corporation prior to its 2007 sale to Inverness Medical and as a director of Digene Corporation prior to its 2007 sale to QIAGEN. He is a member of the board of Venaxis, Inc. (formerly AspenBio Pharma, Inc.), a publicly held diagnostic company, a trustee and member of the governance committee of Christiana Care Health System, a diversified healthcare delivery company, and an advisor to Water Street Health Care Partners. Mr. Landon received a B.S. degree in chemical engineering from the University of Arizona. |
Daniel Levangie |
Mr. Daniel J. Levangie is an Independent Director of LipoScience Inc., since November 2010. He serves as a director of and as chief executive officer of Dune Medical Devices, Inc., a privately held medical device company. He serves as principal and managing partner of Constitution Medical Investors, Inc., a private investment firm focused on healthcare sector-related acquisitions. Mr. Levangie served as president, chief executive officer and a director of Keystone Dental, a dental implant device company, from March 2009 until March 2011. From 2008 to 2009, he served as executive vice president of Cytyc Corporation, a medical equipment and device company targeting women’s health and cancer, and president of Cytyc Surgical Products, a wholly-owned subsidiary of Cytyc, from July 2006 until the acquisition of Cytyc by Hologic, Inc. in October 2007. Prior to July 2006, Mr. Levangie held several positions with Cytyc, including executive vice president and chief commercial officer from 2004 to 2006, chief executive officer and president of Cytyc Health Corporation from 2002 to 2003 and executive vice president and chief operating officer from 2000 to 2002. Prior to joining Cytyc in 1994, Mr. Levangie was employed in several sales and marketing positions by Abbott Laboratories, a diversified healthcare company. Mr. Levangie is currently a director of Exact Sciences Corp., a publicly held diagnostics company, and Insulet Corporation, a publicly held medical device company. During the last five years, he served as a director of ev3, Inc., Cytyc and Hologic. Mr. Levangie received a B.S. degree in pharmacy from Northeastern University. |
Woodrow Myers |
Dr. Woodrow A. Myers is an Independent Director of LipoScience Inc., since March 2011. He has served as managing director of Myers Ventures LLC, a healthcare and education consulting company, since December 2005. He was the executive vice president and chief medical officer of WellPoint, Inc., a commercial health benefits company, from 2000 to 2005. From 1995 to 2000, Dr. Myers also served as the director of healthcare management at the Ford Motor Company. Dr. Myers serves as a director of Express Scripts, Inc. and Genomic Health, Inc. and serves as the chairman of the board of the Mozambique Healthcare Consortium. In addition, Dr. Myers has served as a director of other public companies within the last five years, including ThermoGenesis Corp. from June 2006 to December 2009 and CardioNet, Inc. from August 2007 to May 2009. He is a former health commissioner for New York City and the State of Indiana, past chairman of the visiting committee for the Harvard School of Public Health and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. Dr. Myers holds a B.S. degree in biological sciences from Stanford University, an M.D. degree from Harvard Medical School and an M.B.A. degree from Stanford University. |
Roderick Young |
Mr. Roderick A. Young is an Independent Director of LipoScience Inc. Mr. Young has been a venture partner of Three Arch Partners since May 2006. He served as a director of North American Scientific, Inc., a publicly held medical device company, from 2006 to 2009. From 2003 to 2005, Mr. Young was president and chief executive officer of Vivant Medical, Inc., a venture-backed medical device company that was acquired by Tyco International, Ltd. Prior to his tenure at Vivant, Mr. Young was president and chief executive officer of Targesome, Inc., a biotechnology company, from 1998 to 2002. Prior to Targesome, Mr. Young served as chairman and chief executive officer of General Surgical Innovations, a medical device company; president and chief executive officer of Focus Surgery; president of Toshiba America MRI; and president and chief operating officer of Diasonics. Mr. Young received a B.S. degree in industrial engineering from Stanford University and an M.B.A. degree from Harvard Business School. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Buzz Benson |
-- |
Richard Brajer |
734,727 |
Lucy Martindale |
431,053 |
James Otvos |
242,537 |
Timothy Fischer |
1,019,040 |
Ashok Marin |
-- |
E. Duffy McDonald |
-- |
Thomas Clement |
655,167 |
Robert Honigberg |
523,843 |
Robert Greczyn |
-- |
John Landon |
-- |
Daniel Levangie |
-- |
Woodrow Myers |
-- |
Roderick Young |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Buzz Benson |
0 | 0 |
Richard Brajer |
0 | 0 |
Lucy Martindale |
120,000 | 949,200 |
James Otvos |
132,000 | 1,263,379 |
Timothy Fischer |
0 | 0 |
Ashok Marin |
0 | 0 |
E. Duffy McDonald |
0 | 0 |
Thomas Clement |
0 | 0 |
Robert Honigberg |
0 | 0 |
Robert Greczyn |
0 | 0 |
John Landon |
0 | 0 |
Daniel Levangie |
0 | 0 |
Woodrow Myers |
0 | 0 |
Roderick Young |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
GRECZYN ROBERT J JR |
1,122 | $0.00 |
MYERS WOODROW A JR |
1,122 | $0.00 |
LEVANGIE DANIEL J |
1,122 | $0.00 |
YOUNG RODERICK A |
1,122 | $0.00 |
BARBER JEFFREY T |
2,058 | $0.00 |
BENSON BUZZ |
1,609 | $0.00 |
LANDON JOHN H |
1,122 | $0.00 |
BRAJER RICHARD O |
46,438 | $2.49 |
MCDONALD E DUFFY |
3,765 | $9.65 |
BRAJER RICHARD O |
9,682 | $9.65 |
CLEMENT THOMAS S |
4,062 | $9.65 |
FISCHER TIMOTHY J |
5,063 | $9.65 |
HONIGBERG ROBERT M |
3,563 | $9.65 |
MARTINDALE LUCY G |
4,485 | $9.65 |
OTVOS JAMES D |
3,151 | $9.65 |
SANDERS CHARLES ADDISON |
3,600 | $9.65 |
BENSON BUZZ |
50,000 | $9.00 |
THREE ARCH CAPITAL L P |
72,646 | $0.00 |
BENSON BUZZ |
788,834 | $0.00 |
THREE ARCH CAPITAL L P |
9,705 | $9.00 |
SANDERS CHARLES ADDISON |
1,114 | $0.00 |
OTVOS JAMES D |
7,370 | $0.00 |
THREE ARCH CAPITAL L P |
1,536,688 | $0.00 |
THREE ARCH CAPITAL L P |
205,295 | $9.00 |

